biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by BearDownAZon Mar 22, 2017 1:47pm

137 Views

Post# 26015198

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:MY TAKE.......

JD,

You make good points. However, I am not suggesting that they do a non-human primate (NHP) study NOW in parallel with the Phase 0 study in humans. That ship has sailed. Missed opportunity. IF they are proceeding with Phase 0 in humans, and IF this Phase 0 is able to provide evidence that their Transcendpep (Mtfp) is able to courier some payload across the BBB that is otherwise unable to cross without Mtfp, then this would supercede the need for the NHP validation. I say IF on the Phase 0 because we don't know the study design/goals. My main point was that if Bioasis was so set on the business model of licensing out Mtfp based upon pre-clinical research, then it would have benefited their portfolio of pre-clinical research to include a NHP study. Yes, a company might have needed to do their own NHP study with their own specific Mtfp-drug conjugate/fusion in the course of their own pre-clinical validation. This data would likely be proprietary and no guarantee that the partner would allow Bioasis to share it with others. If Bioasis had done their own NHP validation, then they could flaunt it as freely as they would like.

BDAZ

Bullboard Posts

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload